[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,537,912
  • Shares Outstanding, K 195,861
  • Annual Sales, $ 502,080 K
  • Annual Income, $ -724,930 K
  • EBIT $ -525 M
  • EBITDA $ -514 M
  • 60-Month Beta 1.02
  • Price/Sales 27.42
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 48.79% (+4.83%)
  • Historical Volatility 40.95%
  • IV Percentile 21%
  • IV Rank 25.08%
  • IV High 80.30% on 02/05/26
  • IV Low 38.24% on 06/12/25
  • Expected Move (DTE 26) 6.04 (8.73%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 1,222
  • Volume Avg (30-Day) 2,229
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 47,923
  • Open Int (30-Day) 52,740
  • Expected Range 63.09 to 75.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.62
  • Number of Estimates 9
  • High Estimate $-0.42
  • Low Estimate $-0.88
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +34.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.63 +8.63%
on 05/18/26
84.75 -18.44%
on 04/28/26
-5.32 (-7.15%)
since 04/22/26
3-Month
62.77 +10.12%
on 03/03/26
84.75 -18.44%
on 04/28/26
+0.98 (+1.44%)
since 02/20/26
52-Week
31.77 +117.56%
on 05/29/25
84.94 -18.62%
on 02/12/26
+36.15 (+109.65%)
since 05/22/25

Most Recent Stories

More News
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential...

BBIO : 69.12 (-1.65%)
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1  - All...

BBIO : 69.12 (-1.65%)
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p

BBIO : 69.12 (-1.65%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 69.12 (-1.65%)
BridgeBio Pharma Q1 Earnings Call Highlights

BridgeBio Pharma (NASDAQ:BBIO) reported first-quarter 2026 results highlighted by continued growth for ATTRUBY and increased investment to support three anticipated launches, while also announcing a new...

BBIO : 69.12 (-1.65%)
BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio Pharma: Q1 Earnings Snapshot

BBIO : 69.12 (-1.65%)
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentum...

BBIO : 69.12 (-1.65%)
BridgeBio Pharma: The Commercial Ramp That Analysts Haven't Priced for Friction

Barchart Research What to Expect from BBIO Earnings BBIO Generated May 6, 2026 Current Price $68.09 EPS Estimate $$-0.70 Consensus Rating Strong Buy Average Move 2.86% BridgeBio Pharma: The Commercial...

BBIO : 69.12 (-1.65%)
BridgeBio to Participate in May and June Investor Conferences

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 69.12 (-1.65%)
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date,...

BBIO : 69.12 (-1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 74.43
2nd Resistance Point 73.08
1st Resistance Point 71.10
Last Price 69.12
1st Support Level 67.78
2nd Support Level 66.43
3rd Support Level 64.45

See More

52-Week High 84.94
Last Price 69.12
Fibonacci 61.8% 64.63
Fibonacci 50% 58.36
Fibonacci 38.2% 52.08
52-Week Low 31.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.